Burning Rock Biotech (BNR) Accounts Payables (2019 - 2026)

Burning Rock Biotech's Accounts Payables history runs 8 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 47.17% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (down 47.17% YoY), while the FY2025 annual figure was $5.8 million, up 26.02% from the prior year.
• Accounts Payables for Q1 2026 stood at $2.6 million, down from $5.7 million in the prior quarter.
• The five-year high for Accounts Payables was $15.4 million in Q1 2022, with the low at $2.5 million in Q4 2023.
• The 5-year median for Accounts Payables is $4.5 million (2025), against an average of $5.4 million.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables jumped 102.92% in 2022, then slumped 77.76% in 2023.
• Burning Rock Biotech's Accounts Payables stood at $7.2 million in 2022, then tumbled by 64.98% to $2.5 million in 2023, then soared by 87.29% to $4.7 million in 2024, then gained by 22.27% to $5.7 million in 2025, then plunged by 54.46% to $2.6 million in 2026.
• Business Quant data shows BNR's Accounts Payables at $2.6 million in Q1 2026, $5.7 million in Q4 2025, and $4.8 million in Q3 2025.